{"ticker": {"uuid": "e644d32d-9f57-41ad-9510-648b896d4c8d", "symbol": "PSTV", "name": "Plus Therapeutics Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Plus Therapeutics Secures Regional Coverage Agreement with Medical Mutual for CNSide\u00ae Cerebrospinal Fluid Assay for Metastatic CNS Cancer", "summary": "Plus Therapeutics, through its subsidiary CNSide Diagnostics, LLC, has signed a regional agreement with Medical Mutual to cover its CNSide\u00ae Cerebrospinal Fluid Assay for metastatic CNS cancer. This agreement expands the test's coverage to approximately 1.2 million people in Ohio ", "url": "https://www.sahmcapital.com/news/content/plus-therapeutics-secures-regional-coverage-agreement-with-medical-mutual-for-cnside-cerebrospinal-fluid-assay-for-metastatic-cns-cancer-2026-07-21", "source_name": "Sahm", "published_at": "2026-07-22T00:40:13", "published_display": "22 Jul 2026 00:40", "sentiment": "positive", "sentiment_pct": 80, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Plus Therapeutics secures regional coverage for CNSide\u00ae assay in Ohio and Kentucky, expanding access to 1.2M people.", "summary": "Plus Therapeutics' subsidiary, CNSide Diagnostics, has secured a regional agreement with Medical Mutual, extending coverage for its CNSide Cerebrospinal Fluid Tumor Cell Enumeration assay to 1.2 million people in Ohio and Kentucky. This expansion brings the total national coverag", "url": "https://pluang.com/en/news-feed/plus-therapeutics-amankan-perjanjian-penutupan-regional-dengan-medical-mutual", "source_name": "Pluang", "published_at": "2026-07-21T12:10:22", "published_display": "21 Jul 2026 12:10", "sentiment": "positive", "sentiment_pct": 90, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Plus Therapeutics' CNSide Tests Influenced Treatment Decisions in 90% of Cases", "summary": "Plus Therapeutics, through its subsidiary CNSide Diagnostics, secured a regional coverage agreement with Medical Mutual, effective July 1, 2026, which expands CNSide\u00ae cerebrospinal fluid assay coverage to an additional 1.2 million people in Ohio and Kentucky. This agreement incre", "url": "https://www.stocktitan.net/news/PSTV/plus-therapeutics-secures-regional-coverage-agreement-with-medical-zq3clf8tt003.html", "source_name": "Stock Titan", "published_at": "2026-07-21T11:30:18", "published_display": "21 Jul 2026 11:30", "sentiment": "positive", "sentiment_pct": 89, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PLUS THERAPEUTICS INC (PSTV) Stock Chart", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZEFVX3lxTE02UHpfeFEzU3JVeTFZakU5T2lsQ21sLUhNcUtIdXhLbFJsX1dZUjU5MlFvZVB4LWxtVHNZZXB6OFpNWlR6cEdKZlYxOE9pSFQ0eGg4ZDV5RXBJY090dmNfOTJybkc?oc=5", "source_name": "ChartMill", "published_at": "2026-07-18T00:09:03+00:00", "published_display": "18 Jul 2026 00:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Plus Therapeutics partners with GTC on CSF diagnostic platform By Investing.com", "summary": "Plus Therapeutics (NASDAQ: PSTV) has announced a partnership with Genomic Testing Cooperative (GTC) to integrate next-generation sequencing technology into its CNSide cerebrospinal fluid assay platform. This collaboration aims to enhance the CNSide platform by enabling DNA and RN", "url": "https://ng.investing.com/news/stock-market-news/plus-therapeutics-partners-with-gtc-on-csf-diagnostic-platform-93CH-2602811", "source_name": "Investing.com Nigeria", "published_at": "2026-07-16T22:39:42", "published_display": "16 Jul 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Plus Therapeutics, Genomic Testing Cooperative to Integrate NGS Technology Into CNSide CSF Assay Platform", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/plus-therapeutics-genomic-testing-cooperative-120442790.html", "source_name": "MT Newswires", "published_at": "2026-07-16T12:04:42+00:00", "published_display": "16 Jul 2026 12:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cancer guidelines broaden spinal-fluid analysis; Plus plans DNA, RNA", "summary": "Plus Therapeutics (Nasdaq: PSTV) announced a collaboration with Genomic Testing Cooperative (GTC) to integrate next-generation sequencing into its CNSide cerebrospinal fluid assay platform. This partnership aims to enable comprehensive DNA and RNA profiling of hundreds of biomark", "url": "https://www.stocktitan.net/news/PSTV/plus-therapeutics-and-genomic-testing-cooperative-partner-to-o6lcf49lmxww.html", "source_name": "Stock Titan", "published_at": "2026-07-16T11:10:35", "published_display": "16 Jul 2026 11:10", "sentiment": "positive", "sentiment_pct": 74, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Plus Therapeutics and Genomic Testing Cooperative Partner to Integrate Next-Generation Sequencing Into the CNSide\u00ae CSF Assay Platform", "summary": "Plus Therapeutics and Genomic Testing Cooperative (GTC) have partnered to integrate next-generation sequencing (NGS) into Plus's CNSide\u00ae cerebrospinal fluid (CSF) assay platform. This collaboration aims to provide comprehensive DNA and RNA profiling of hundreds of biomarkers from", "url": "https://finance.yahoo.com/healthcare/articles/plus-therapeutics-genomic-testing-cooperative-113000632.html", "source_name": "Market source", "published_at": "2026-07-16T10:12:39", "published_display": "16 Jul 2026 10:12", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Plus Therapeutics (PSTV) Updates NCCN Guidelines for CNS Cancers", "summary": "Plus Therapeutics (PSTV) announced updates to the NCCN Guidelines for Central Nervous System Cancers, focusing on improved diagnosis and assessment of leptomeningeal metastases. The company, a clinical-stage pharmaceutical firm with a market cap of $29.26 million, is developing t", "url": "https://www.gurufocus.com/news/8957497/plus-therapeutics-pstv-updates-nccn-guidelines-for-cns-cancers?mobile=true", "source_name": "GuruFocus", "published_at": "2026-07-14T14:41:03", "published_display": "14 Jul 2026 14:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Plus Therapeutics Highlights NCCN CNS Cancers Guidelines Update and Reinforces Clinical Role of CNSide\u00ae in Leptomeningeal Metastases Monitoring", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/plus-therapeutics-highlights-nccn-cns-113000234.html", "source_name": "GlobeNewswire", "published_at": "2026-07-14T11:30:00+00:00", "published_display": "14 Jul 2026 11:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Guidelines call for spinal-fluid checks every 4\u20138 weeks during therapy", "summary": "Plus Therapeutics (PSTV) highlighted an update to the NCCN CNS Cancers Guidelines, which endorse cerebrospinal fluid (CSF) analysis and recommend CSF cytology follow-up every 4\u20138 weeks for leptomeningeal metastases (LM) patients undergoing intrathecal therapy. The company's CNSid", "url": "https://www.stocktitan.net/news/PSTV/plus-therapeutics-highlights-nccn-cns-cancers-guidelines-update-and-czg0vq48mgiu.html", "source_name": "Stock Titan", "published_at": "2026-07-14T11:41:04", "published_display": "14 Jul 2026 11:41", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Plus Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Hawkins Richard J", "summary": "This article consists solely of the title, indicating a statement of changes in beneficial ownership of securities for Director Richard J. Hawkins at Plus Therapeutics. No further details are provided in the content.", "url": "https://www.moomoo.com/news/notice/307648026/plus-therapeutics-4-statement-of-changes-in-beneficial-ownership-of", "source_name": "Moomoo", "published_at": "2026-07-02T01:09:43", "published_display": "02 Jul 2026 01:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Plus Therapeutics (NASDAQ: PSTV) director gains 922 shares via RSU vesting", "summary": "Plus Therapeutics director Howard Clowes acquired 922 shares of common stock through the vesting of restricted stock units (RSUs) as part of his equity compensation. This transaction, filed on Form 4, increased his direct holdings to 1,981 common shares, with an additional 2,764 ", "url": "https://www.stocktitan.net/sec-filings/PSTV/form-4-plus-therapeutics-inc-insider-trading-activity-3d81645b0443.html", "source_name": "Stock Titan", "published_at": "2026-07-01T20:09:43", "published_display": "01 Jul 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PLUS Therapeutics (PSTV) director converts 922 RSUs into common stock", "summary": "PLUS Therapeutics director Ronald Asbury Andrews converted 922 Restricted Stock Units (RSUs) into 922 shares of common stock on July 1, 2026, as part of his compensation, at a stated price of $0.00 per share. Following this transaction, he directly holds 922 shares of common stoc", "url": "https://www.stocktitan.net/sec-filings/PSTV/form-4-plus-therapeutics-inc-insider-trading-activity-b2f1bef9b1b3.html", "source_name": "Stock Titan", "published_at": "2026-07-01T20:09:43", "published_display": "01 Jul 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PLUS Therapeutics (PSTV) director converts RSUs into 922 common shares", "summary": "PLUS Therapeutics director Kyle Guse exercised restricted stock units (RSUs) to acquire 922 shares of common stock at no cost. Following this transaction, Guse directly holds 922 common shares, with an additional 2,764 RSUs remaining outstanding, which will vest in quarterly inst", "url": "https://www.stocktitan.net/sec-filings/PSTV/form-4-plus-therapeutics-inc-insider-trading-activity-6c07411052d3.html", "source_name": "Stock Titan", "published_at": "2026-07-01T20:09:43", "published_display": "01 Jul 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] PLUS THERAPEUTICS, INC. Insider Trading Activity", "summary": "PLUS THERAPEUTICS director Richard J. Hawkins reported an insider trading activity involving the vesting of 922 Restricted Stock Units (RSUs) on July 1, 2026. This transaction was compensation-related, with each RSU converting into one share of common stock at $0.00 per share. Af", "url": "https://www.stocktitan.net/sec-filings/PSTV/form-4-plus-therapeutics-inc-insider-trading-activity-5919bab49dc7.html", "source_name": "Stock Titan", "published_at": "2026-07-01T20:09:43", "published_display": "01 Jul 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Plus Therapeutics (PSTV) CEO gains 16,439 shares from RSU vesting", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxOT0VQN3RXSy1DYm5TYjd3cDg3WUdjcXRkWGFWUDJGXzRZYlZvbU5MckZMOTJTMDM2SEF4dUItdF9xVG5NRG43bkNjRWE5Zi0xREtCZThLTGtsWWFfUEg4SnJnc3kzc1FRNVFUU0dHV1VvX3JMaUN2SDBPckU0aEpDNEtKWVE0R0FhWEtLZnRUTU9tREU4cWFLVE9lTFg2dEVsSEsxT0ljV0NMRVZ3X3IwdXRYZ19EZw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Plus Therapeutics (PSTV) director begins 4-part restricted stock unit vesting", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxPRTl2M255YWhPa1VLVjNFM2llVTRPaDc0bGdvSzJ5bVJRekNZaUx0RXRsdjdZQlRTOThQbzNkTnY5TDl4ZGNHQlRqQ0duVWpuVWlPcWFodGhxT3lqcGtMZmJQaGM0WjRzMzdBdmVFVzJ2bFNGUnpFTDZ3REZBcHNZeDZ0R2JfQThNUkw0ZDJFYUxSOFU0UXFzWDdiUU9USDM0NzltbjJOZXg0azN4WXQ4SmtXZEp5Zw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Plus Therapeutics to rebrand as Cerenome and adopt CNSY ticker on August 3 (PSTV)", "summary": "Plus Therapeutics, a healthcare company focusing on CNS cancers, announced it will rebrand as Cerenome and trade under the new Nasdaq ticker CNSY starting August 3, 2026. The company also reaffirmed its 2026 guidance, highlighting increased insurance coverage for its CNSide diagn", "url": "https://finance.yahoo.com/healthcare/articles/plus-therapeutics-rebrand-cerenome-adopt-124948664.html", "source_name": "Market source", "published_at": "2026-06-30T12:39:16", "published_display": "30 Jun 2026 12:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Plus Therapeutics to rebrand as Cerenome, change ticker to CNSY", "summary": "Plus Therapeutics (NASDAQ:PSTV) will rebrand as Cerenome and change its ticker symbol to CNSY, starting August 3, 2026. The company, which specializes in central nervous system cancers, currently trades at $4.29 with a market capitalization of $29.7 million, despite a 66.5% year-", "url": "https://www.investing.com/news/company-news/plus-therapeutics-to-rebrand-as-cerenome-change-ticker-to-cnsy-93CH-4767582", "source_name": "Investing.com", "published_at": "2026-06-30T11:39:16", "published_display": "30 Jun 2026 11:39", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Plus Therapeutics rebrands as Cerenome, ticker CNSY starts Aug. 3", "summary": "Plus Therapeutics (Nasdaq: PSTV) announced a rebranding to Cerenome with its ticker changing to CNSY, effective August 3, 2026. The company affirmed its 2026 milestone guidance, providing updates on REYOBIQ clinical trials, commercial expansion of its CNSide diagnostic platform, ", "url": "https://www.stocktitan.net/news/PSTV/plus-therapeutics-provides-mid-year-business-update-including-2cqma2y520bz.html", "source_name": "Stock Titan", "published_at": "2026-06-30T11:39:15", "published_display": "30 Jun 2026 11:39", "sentiment": "positive", "sentiment_pct": 78, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Plus Therapeutics Provides Mid-Year Business Update Including Corporate Rebranding", "summary": "Plus Therapeutics is rebranding to Cerenome and will trade under the new Nasdaq ticker CNSY starting August 3, 2026. This change reflects the company's integrated CNS oncology platform, combining therapeutics, diagnostics, and data analytics. The company also affirmed its 2026 gu", "url": "https://www.globenewswire.com/news-release/2026/06/30/3319554/0/en/plus-therapeutics-provides-mid-year-business-update-including-corporate-rebranding.html", "source_name": "GlobeNewswire", "published_at": "2026-06-30T11:39:15", "published_display": "30 Jun 2026 11:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of PLUS THERAPEUTICS, Inc. \u2013 NASDAQ:PSTV", "summary": "This article displays the title \"Price to earnings forward of PLUS THERAPEUTICS, Inc. \u2013 NASDAQ:PSTV\" and provides an overview of the company on TradingView. It indicates that the market is closed and no trades have occurred for PSTV. The content primarily focuses on navigation, m", "url": "https://www.tradingview.com/symbols/NASDAQ-PSTV/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T04:39:16", "published_display": "30 Jun 2026 04:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of PLUS THERAPEUTICS, Inc. \u2013 NASDAQ:PSTV", "summary": "This article provides financial data, specifically the \"Price to sales forward,\" for PLUS THERAPEUTICS, Inc. (NASDAQ: PSTV). It appears to be a financial snapshot from TradingView, offering details within a larger platform context. The content presents the \"Period,\" \"Value,\" \"Cha", "url": "https://www.tradingview.com/symbols/NASDAQ-PSTV/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T19:10:47", "published_display": "29 Jun 2026 19:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Plus Therapeutics to Provide Business Update Call on June 30, 2026", "summary": "Plus Therapeutics (Nasdaq: PSTV) announced it will host a business update call and webcast on Tuesday, June 30, 2026, at 8:30 a.m. Eastern Time. Management will discuss the CNSide\u00ae diagnostic launch, its integrated development plan for Reyobiq, and provide details on its CNS onco", "url": "https://www.globenewswire.com/news-release/2026/06/23/3315850/0/en/plus-therapeutics-to-provide-business-update-call-on-june-30-2026.html", "source_name": "GlobeNewswire", "published_at": "2026-06-27T06:09:04", "published_display": "27 Jun 2026 06:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Plus Therapeutics, Inc. Actuals & Estimates (DUS:XMP1)", "summary": "This article provides an overview of Plus Therapeutics, Inc. (DUS:XMP1) financials, analyst estimates, and key stock performance metrics. It includes details on past earnings, revenue, net income, and future earnings estimates. The article also covers the stock's highest and lowe", "url": "https://www.tradingview.com/symbols/DUS-XMP1/forecast-actuals-and-estimates/?category=cash_flow", "source_name": "TradingView", "published_at": "2026-06-27T02:40:11", "published_display": "27 Jun 2026 02:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Plus Therapeutics, Inc. Actuals & Estimates (GETTEX:XMP1)", "summary": "This article provides an overview of Plus Therapeutics, Inc. (XMP1) stock on GETTEX, including its current price, historical performance, analyst forecasts, and key financial metrics. It details income statement, balance sheet, and cash flow data, as well as upcoming earnings rep", "url": "https://www.tradingview.com/symbols/GETTEX-XMP1/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T15:39:44", "published_display": "26 Jun 2026 15:39", "sentiment": "negative", "sentiment_pct": 39, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Plus Therapeutics Secures National Coverage Agreement with Elevance Health for CNSide\u00ae Cerebrospinal Fluid Assay for Metastatic CNS Cancer", "summary": "Plus Therapeutics Inc., through its subsidiary CNSide Diagnostics, LLC, has announced a national agreement with Elevance Health, Inc. This agreement, effective May 1, 2026, extends coverage for the CNSide\u00ae Cerebrospinal Fluid (CSF) Tumor Cell Enumeration (TCE) assay to approximat", "url": "https://finance.yahoo.com/healthcare/articles/plus-therapeutics-secures-national-coverage-113000305.html", "source_name": "Market source", "published_at": "2026-06-25T23:11:14", "published_display": "25 Jun 2026 23:11", "sentiment": "positive", "sentiment_pct": 80, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Plus Therapeutics Unit Signs Coverage Agreement With Elevance Health for CNSide Assay", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/plus-therapeutics-unit-signs-coverage-121726944.html", "source_name": "MT Newswires", "published_at": "2026-06-25T12:17:26+00:00", "published_display": "25 Jun 2026 12:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Plus Therapeutics gets national health coverage for CNS cancer test", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPQ1p1TTZyc1lEcFd1eHRRZW1fUnlpX1B5U1gxeFltenVDc294MEtIczB0cWdXbGt5UWR6am5Rd2xSTi1mMHVSYkVLM1RHaGF3cXYwemR0czZyVkM5TC1TR0d2RzZpbUstZTdiT3RHQ3BuRV9GQ2JMYkVUN0NxZXRZQ3ZwT3BQbjhjNGdseVNmNGJQQmJZMG9kdTgwTDVYdk9PRG5BUjc4OWtCal9FWDh1VXFpcHQ0NjZTdmQ1eWFKdw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Plus Therapeutics to detail CNSide launch, Reyobiq plan June 30", "summary": "Plus Therapeutics (Nasdaq: PSTV) announced it will host a business update conference call and webcast on June 30, 2026, at 8:30 a.m. ET. Management plans to discuss the launch of its CNSide diagnostic, the integrated development plan for its lead drug Reyobiq, its CNS oncology st", "url": "https://www.stocktitan.net/news/PSTV/plus-therapeutics-to-provide-business-update-call-on-june-30-36v2qygbjoll.html", "source_name": "Stock Titan", "published_at": "2026-06-23T11:11:11", "published_display": "23 Jun 2026 11:11", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Plus Therapeutics Inc (PSTV) Risk Assessment: Volatility, Financial Risk & Investment Risk", "summary": "This article provides a risk assessment for Plus Therapeutics Inc (PSTV), detailing its volatility, financial risk, and investment risk. The company has a risk assessment score of 2.81, ranking 186 out of 388 in the Biotechnology & Medical Research industry, and its beta value of", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-pstv/risk-assesment", "source_name": "TradingKey", "published_at": "2026-06-17T09:40:35", "published_display": "17 Jun 2026 09:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Plus Therapeutics Inc (PSTV) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a detailed revenue breakdown for Plus Therapeutics Inc (PSTV) for fiscal year 2018, updated as of March 4, 2025. It categorizes revenue by business segments, including Consumable, Other products, and Device, and by geographic regions, specifically Japan, Ame", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-pstv/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T06:40:35", "published_display": "17 Jun 2026 06:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PLUS THERAPEUTICS, INC. SEC Filing (Jun 8, 2026)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxQOWN2bTFpaWhrTWVuVEctZW45ZlJHZWd0amZxNkpnRGVzYTVzdV8yMjBiMy1IaWJlTmRVdHVNcVpyUlpSZTBoTl9ia3c2blh0M2h2Wlk1UzhkdXpESy1aLVhtTFZndGUyTnNNWF84ajlwakRvQzE4bW4xSzFGWVN6eUwyWG14U2JfZEJFbzhjdUNZNnlHOHFjaFdLWnRLOUd3a3Ew?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Plus Therapeutics (NASDAQ: PSTV) sets $17,350,000 at-the-market stock program", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxPak1vVEQ4TnhFYlYxcVZBRFNfbjRObFUtNmg3dWxZMjNTSXF6OTlQUDA3and6OHRZa204WFIxUVVwd3JQcnpZUVBWamZPSl9aVGtveGZLUEd5YkpPc3hKVXJUR0JCcnY5U0lESFkyLW4xeERDek5FTldjajU3dE1vU0k5TmdZZnVZSzRjRUtIOXdsM3FDbVpCdHhCYVQ0OFNCczM4M0tYelRCOVRiZ2Uw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Plus Therapeutics gains CAP accreditation for CNSide CSF assay platform", "summary": "", "url": "https://finance.yahoo.com/m/d1b21ffe-1150-36de-8440-f3c64ad347ef/plus-therapeutics-gains-cap.html", "source_name": "Proactive", "published_at": "2026-06-04T16:17:00+00:00", "published_display": "04 Jun 2026 16:17", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What Do Plus Therapeutics' Latest Financials Tell Us", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxPekpCUVdsWFhIeS0xVGwtWWd2MVR5OHJQVkFXTlBoZ01aaFNoTWJiNmwzVjNMMVVpc1lOblVIdC1KV3pOYVhwMk9oRUNJQUxhX19uc1hkRF9jNzFWaWhKT0p3SUp4bDhJNld3MEp2S2lzdXpCRW05d2xBUE9zcEVHRUhXaVBVeEQ1cml3TUNUYw?oc=5", "source_name": "Kavout | AI", "published_at": "2026-05-16T00:05:51+00:00", "published_display": "16 May 2026 00:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Plus Therapeutics (PSTV) Reports Q1 Loss, Tops Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxOOUxjSVRTWlVTcDRBbVRGdmxCZUlBNEdOb2FXUnQ3TWFBTGNaampsOUtZODZPR3NfNHVYdE9BOVRNQUd5RF81bjlIODlGdkpGWEpwVkpYVExxYzNzY0lIdmFKZXpSYi1EWS1rTzRYTjh6WWhLeHY4Q1g2aGxTUVpWUnV3T1p1TXFvS1FDbUY5ZjJpMzVMVkdLcEtYem4waWhmU0dvNA?oc=5", "source_name": "Market source", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Plus Therapeutics stock gains after FDA orphan drug nod", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxQQXR3SE1YM2JBTHgtMHk3allveWJkckhOd0tuU2pQZXFPV3ZZM2pIdXNOYVFkRzdWMjhxejRkTEsxN3loUTYxNk9zQkNBY2J0YV90cm5lRk03WTZUb1VES2dVdGd1RjdoYmNzb0ZPc2IweG9taFAtczhReVd0bWphOXY1RWw0ZHdEZmVheEpLOU5HOUlYS0Q3b0Q0cEtHbmpLekhucDBuQ3ZFTDh2MGQ1Qy1WakpERDF6?oc=5", "source_name": "Investing.com", "published_at": "2026-04-08T07:00:00+00:00", "published_display": "08 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA grants orphan drug status to Plus Therapeutics\u2019 REYOBIQ", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxQTWdycXJpZmFIZm0yVUlPekh5T3pWTkE0eWpyaVdmS1BaSlBKckZZcGpyY0VuNEtlck8zNjBpVXJnenJSS2FqS3JzdG9Oek9GODVRQ1hzOFU3UDNKR0tlMVRNSGY1SFpxcTVrR2pGMll6b1pWMXVETl9fOUR5cWxIeUlBMnBuRmpUdHBQNEJldC1tR3FPU1BPQXU4M1M3SFpFMXBIQUxfcWFSalpobDBtekkycTAwUQ?oc=5", "source_name": "Investing.com", "published_at": "2026-04-08T07:00:00+00:00", "published_display": "08 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "D. Boral Capital Downgrades Plus Therapeutics (PSTV) to Hold", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxNa0JfWlJBYkpQZnpfNmdIMjVjTE1GZWp4Y0NLRjJHUkhibFQ4d0hiZ0Q1UWxjdzNLZG93OEt2TzJITUMxSTBUaEgxNU90Unk0N1ZuUWdaQjMxMC1hZnJvd1VTMTFmZjdHVkFObU5vTWpEeVZjUUNiOU9hem4yTUNiN3VtM3VETVdqb1pOUDR3RzIzQjBrcW5kZGk4czU?oc=5", "source_name": "Market source", "published_at": "2026-04-07T07:00:00+00:00", "published_display": "07 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Plus Therapeutics Announces Reverse Stock Split", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQYnhEZzFkTnR4aGVoRUttV1VraFZQc2JVMElONl9maENfMk8xS0VERjA1TF9MWDJycGRVbzZBN2pURDZPYXFHM1UwSUI2LXUzV0U0XzF3ZExUYTBQbm5MdTRLc1BtcHUwZjA2ZXl4cGZheklmSkNmMjJxM29CV2xWMS1LOGNjRWU2X19HNUJNQk44UXFObGNxdmt4bncwTGFZSDl3dC1Ga2gtdw?oc=5", "source_name": "Market source", "published_at": "2026-03-31T07:00:00+00:00", "published_display": "31 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Plus Therapeutics (PSTV) Reports Break-Even Earnings for Q4", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxPcV9yZ2d6NE9pWHVHTzVHMmEweE9UOEFvOURPa2Fsa3JCQ3JONk42bXVKUkR5bkY0al9qbGJzc05ZYzVGX2k0LXZySjVtU3F5YTRIN2VUNW5UTUktRF9heFZjYUhFbHp3LXJPTWwxWFB0VE5KNXFKenNVbXRYd1ROOGJkMC1RV2ZtMXc?oc=5", "source_name": "Market source", "published_at": "2026-03-12T07:00:00+00:00", "published_display": "12 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Analyst Revisions Are Rewriting The Story For Plus Therapeutics (PSTV)", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxOSTVvaEtiOUZSOWVPVnhBOHlnLURsUEN2ZjJEWFdsaURXNW5tTUE5em1VeGJFdWtXMUw4U0VxRjhBQzNlWmRVWU01Vnd1dVVnc09nZTJVdTBxWjJ5cjZwM3ZaVTEybEFOX3JZQzI2QTFoOHdCLXd2X1NhUk5HMGR0b1ZtR1dMYWRTN2syTQ?oc=5", "source_name": "Market source", "published_at": "2026-02-06T08:00:00+00:00", "published_display": "06 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Plus Therapeutics Provides Business Update on REYOBIQ\u2122 Clinical Program and U.S. CNSide\u00ae Commercialization", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxPUXZOLWNyNGZ6blY1dUVQZUF4NEEybEhBRGZwbEtrSlBWV1AzQVVzRXZ3dlA5aWRad3V0bmxaVU9tUnh6WkluUHIycm5qRlN1dHpaUXZtYWluLVdtSUFaRnlKdXE2ekJMMzhMNDVSZXRTX0xSOFpjcWdjS0JLSWVxcF9ONm1MbXlwc2lacWM1Nnh0cTA?oc=5", "source_name": "Market source", "published_at": "2026-01-22T08:00:00+00:00", "published_display": "22 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Plus Therapeutics plans CNS cancer test coverage for 150M US lives", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxQS211ak15NHFfSUhldWpQalR2U3VzbWZ5MzVhM3VQOUN5ME52Z2l2LUU4OHZSaE9IVXJqaGlZaVFmMHIxa3VUbDd5N3A0d2cxb1B5dDdKOXdSRFhhNG50Sk5QVnJ1WG9jWnN1OXc0Qm9DMWJ1eXRoY2ZDXzZzaThxUGwzZGJnTnl3a010Z3loMGhXMDkxczFTRkYtdFdYZ0IwU01sNmw4Zlhza1BNU3JsN3NxenktY0d4OUdn?oc=5", "source_name": "Stock Titan", "published_at": "2026-01-22T08:00:00+00:00", "published_display": "22 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Plus Therapeutics completes FDA meeting on REYOBIQ trial strategy", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPRHFPdUJ3YkxtVnlxblQ2YXViUER5YlJ2d0VYcGpQbS1lV21GODlzaVl5TkJkNlZvRDNNNTZkakVqYVZEa09DZFllMDdCa0E1NXlVeUVsdExvN1FrVURVOHB5bklzTHl2U01LN1FMQWxNc1dJOHlvZ1FIZHZWMnFueHVKSzRlMExOMk92eVNHa3hqYWJTUV9udkQ0VDRzWmVtUFFSa1JfR2w0SjJHV0RfOTk3OUtvcHBZX3RsdVZMQQ?oc=5", "source_name": "Investing.com", "published_at": "2026-01-08T08:00:00+00:00", "published_display": "08 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Plus Therapeutics stock falls after FDA meeting on REYOBIQ trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxQQkNzSkdmNE1hMWs2a3gyVGg3WVR5NHdqelZLbzhJenRnU24yTk9HTXo5cjVNWUdGb1U4ZVdsSGZNeXlOaFVyaEdwWEVkUDBZMGtEbTR4VHlTZm5kTk1EZ2hNSzNUdF9namNrd2xZNlZoOWp0cTJycmNyQmlGcExUMUFBSUdjNjIxc05MVkFYRnpZRVVHVzNXVGh3ZnFlancwLU1mdkJ3cnZzMVVWd281V0hPTlVKT2RHTXZKZFRRVC13d193?oc=5", "source_name": "Investing.com", "published_at": "2026-01-08T08:00:00+00:00", "published_display": "08 Jan 2026 08:00", "sentiment": "negative", "sentiment_pct": 22, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Plus Therapeutics Announces National Coverage Agreement with UnitedHealthcare Insurance Company for CNSide\u00ae Cerebrospinal Fluid Assay for Metastatic CNS Cancer", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgJBVV95cUxOZGh5eWxDV0QzU2NTMHlXVXcxYVRMbEM5Ql9lanpyel9FZVpQdWJLY2lZTGp3dGp2SzhOcVZ1WXJ2WjFjWERLbXRBTTR3el9fTFVNOEE3NWZtUFlqQTByTUJzOHRUTHFRdUJPSFdWZkRYbkgtOTYtajB6dHBFRXdLWmhfWXNESGZmYmtsZHJLZkxwT1BCd1MweHFUeVRKTXBMUWV2VGF0Q3BBX0pnclVwQ1ItNm5fcU9MTWEwblJIMmhkdzZEa1JVX2ViVlg3RXF6bTZocF84TlMydGtUbF9QMnA4cDcyUXc5b1BTRVUyOUlBeG5EbUhta0FnMVk1azRMVXZVVlJXZWs0b2tlTURCWXBadHBpdw?oc=5", "source_name": "Investing News Network", "published_at": "2025-09-25T07:00:00+00:00", "published_display": "25 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Plus Therapeutics Announces National Coverage Agreement with UnitedHealthcare For CNS Cancer Diagnostic Kit", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxQUnFtSmM1QzNRajhFenhkTEdqRFNmWENZam1jSURHRHdZZl8zbDV1Rk9xM3NGeG13M01OUk1maktabkkta253YXdkMU9nazItbVVmSnBvZlRVUGFHNTlrdTVQeHUyclFIYmdIQVJoSEJaeW5hcHVFSHJIalNhYmVjcVhLOVZvbjBYYXdheVpQaHhNOGg0cEE?oc=5", "source_name": "Market source", "published_at": "2025-09-25T07:00:00+00:00", "published_display": "25 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We Think Plus Therapeutics (NASDAQ:PSTV) Needs To Drive Business Growth Carefully", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-08-15T07:00:00+00:00", "published_display": "15 Aug 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Plus Therapeutics Secures Regional Coverage Agreement with Medical Mutual for CNSide\u00ae Cerebrospinal Fluid Assay for Metastatic CNS Cancer", "summary": "Plus Therapeutics, through its subsidiary CNSide Diagnostics, LLC, has signed a regional agreement with Medical Mutual to cover its CNSide\u00ae Cerebrospinal Fluid Assay for metastatic CNS cancer. This agreement expands the test's coverage to approximately 1.2 million people in Ohio ", "url": "https://www.sahmcapital.com/news/content/plus-therapeutics-secures-regional-coverage-agreement-with-medical-mutual-for-cnside-cerebrospinal-fluid-assay-for-metastatic-cns-cancer-2026-07-21", "source_name": "Sahm", "published_at": "2026-07-22T00:40:13", "published_display": "22 Jul 2026 00:40", "sentiment": "positive", "sentiment_pct": 80, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Plus Therapeutics secures regional coverage for CNSide\u00ae assay in Ohio and Kentucky, expanding access to 1.2M people.", "summary": "Plus Therapeutics' subsidiary, CNSide Diagnostics, has secured a regional agreement with Medical Mutual, extending coverage for its CNSide Cerebrospinal Fluid Tumor Cell Enumeration assay to 1.2 million people in Ohio and Kentucky. This expansion brings the total national coverag", "url": "https://pluang.com/en/news-feed/plus-therapeutics-amankan-perjanjian-penutupan-regional-dengan-medical-mutual", "source_name": "Pluang", "published_at": "2026-07-21T12:10:22", "published_display": "21 Jul 2026 12:10", "sentiment": "positive", "sentiment_pct": 90, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Plus Therapeutics' CNSide Tests Influenced Treatment Decisions in 90% of Cases", "summary": "Plus Therapeutics, through its subsidiary CNSide Diagnostics, secured a regional coverage agreement with Medical Mutual, effective July 1, 2026, which expands CNSide\u00ae cerebrospinal fluid assay coverage to an additional 1.2 million people in Ohio and Kentucky. This agreement incre", "url": "https://www.stocktitan.net/news/PSTV/plus-therapeutics-secures-regional-coverage-agreement-with-medical-zq3clf8tt003.html", "source_name": "Stock Titan", "published_at": "2026-07-21T11:30:18", "published_display": "21 Jul 2026 11:30", "sentiment": "positive", "sentiment_pct": 89, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PLUS THERAPEUTICS INC (PSTV) Stock Chart", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZEFVX3lxTE02UHpfeFEzU3JVeTFZakU5T2lsQ21sLUhNcUtIdXhLbFJsX1dZUjU5MlFvZVB4LWxtVHNZZXB6OFpNWlR6cEdKZlYxOE9pSFQ0eGg4ZDV5RXBJY090dmNfOTJybkc?oc=5", "source_name": "ChartMill", "published_at": "2026-07-18T00:09:03+00:00", "published_display": "18 Jul 2026 00:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Plus Therapeutics partners with GTC on CSF diagnostic platform By Investing.com", "summary": "Plus Therapeutics (NASDAQ: PSTV) has announced a partnership with Genomic Testing Cooperative (GTC) to integrate next-generation sequencing technology into its CNSide cerebrospinal fluid assay platform. This collaboration aims to enhance the CNSide platform by enabling DNA and RN", "url": "https://ng.investing.com/news/stock-market-news/plus-therapeutics-partners-with-gtc-on-csf-diagnostic-platform-93CH-2602811", "source_name": "Investing.com Nigeria", "published_at": "2026-07-16T22:39:42", "published_display": "16 Jul 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Plus Therapeutics, Genomic Testing Cooperative to Integrate NGS Technology Into CNSide CSF Assay Platform", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/plus-therapeutics-genomic-testing-cooperative-120442790.html", "source_name": "MT Newswires", "published_at": "2026-07-16T12:04:42+00:00", "published_display": "16 Jul 2026 12:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cancer guidelines broaden spinal-fluid analysis; Plus plans DNA, RNA", "summary": "Plus Therapeutics (Nasdaq: PSTV) announced a collaboration with Genomic Testing Cooperative (GTC) to integrate next-generation sequencing into its CNSide cerebrospinal fluid assay platform. This partnership aims to enable comprehensive DNA and RNA profiling of hundreds of biomark", "url": "https://www.stocktitan.net/news/PSTV/plus-therapeutics-and-genomic-testing-cooperative-partner-to-o6lcf49lmxww.html", "source_name": "Stock Titan", "published_at": "2026-07-16T11:10:35", "published_display": "16 Jul 2026 11:10", "sentiment": "positive", "sentiment_pct": 74, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Plus Therapeutics and Genomic Testing Cooperative Partner to Integrate Next-Generation Sequencing Into the CNSide\u00ae CSF Assay Platform", "summary": "Plus Therapeutics and Genomic Testing Cooperative (GTC) have partnered to integrate next-generation sequencing (NGS) into Plus's CNSide\u00ae cerebrospinal fluid (CSF) assay platform. This collaboration aims to provide comprehensive DNA and RNA profiling of hundreds of biomarkers from", "url": "https://finance.yahoo.com/healthcare/articles/plus-therapeutics-genomic-testing-cooperative-113000632.html", "source_name": "Market source", "published_at": "2026-07-16T10:12:39", "published_display": "16 Jul 2026 10:12", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Plus Therapeutics (PSTV) Updates NCCN Guidelines for CNS Cancers", "summary": "Plus Therapeutics (PSTV) announced updates to the NCCN Guidelines for Central Nervous System Cancers, focusing on improved diagnosis and assessment of leptomeningeal metastases. The company, a clinical-stage pharmaceutical firm with a market cap of $29.26 million, is developing t", "url": "https://www.gurufocus.com/news/8957497/plus-therapeutics-pstv-updates-nccn-guidelines-for-cns-cancers?mobile=true", "source_name": "GuruFocus", "published_at": "2026-07-14T14:41:03", "published_display": "14 Jul 2026 14:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Plus Therapeutics Highlights NCCN CNS Cancers Guidelines Update and Reinforces Clinical Role of CNSide\u00ae in Leptomeningeal Metastases Monitoring", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/plus-therapeutics-highlights-nccn-cns-113000234.html", "source_name": "GlobeNewswire", "published_at": "2026-07-14T11:30:00+00:00", "published_display": "14 Jul 2026 11:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Guidelines call for spinal-fluid checks every 4\u20138 weeks during therapy", "summary": "Plus Therapeutics (PSTV) highlighted an update to the NCCN CNS Cancers Guidelines, which endorse cerebrospinal fluid (CSF) analysis and recommend CSF cytology follow-up every 4\u20138 weeks for leptomeningeal metastases (LM) patients undergoing intrathecal therapy. The company's CNSid", "url": "https://www.stocktitan.net/news/PSTV/plus-therapeutics-highlights-nccn-cns-cancers-guidelines-update-and-czg0vq48mgiu.html", "source_name": "Stock Titan", "published_at": "2026-07-14T11:41:04", "published_display": "14 Jul 2026 11:41", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Plus Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Hawkins Richard J", "summary": "This article consists solely of the title, indicating a statement of changes in beneficial ownership of securities for Director Richard J. Hawkins at Plus Therapeutics. No further details are provided in the content.", "url": "https://www.moomoo.com/news/notice/307648026/plus-therapeutics-4-statement-of-changes-in-beneficial-ownership-of", "source_name": "Moomoo", "published_at": "2026-07-02T01:09:43", "published_display": "02 Jul 2026 01:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Plus Therapeutics (NASDAQ: PSTV) director gains 922 shares via RSU vesting", "summary": "Plus Therapeutics director Howard Clowes acquired 922 shares of common stock through the vesting of restricted stock units (RSUs) as part of his equity compensation. This transaction, filed on Form 4, increased his direct holdings to 1,981 common shares, with an additional 2,764 ", "url": "https://www.stocktitan.net/sec-filings/PSTV/form-4-plus-therapeutics-inc-insider-trading-activity-3d81645b0443.html", "source_name": "Stock Titan", "published_at": "2026-07-01T20:09:43", "published_display": "01 Jul 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PLUS Therapeutics (PSTV) director converts 922 RSUs into common stock", "summary": "PLUS Therapeutics director Ronald Asbury Andrews converted 922 Restricted Stock Units (RSUs) into 922 shares of common stock on July 1, 2026, as part of his compensation, at a stated price of $0.00 per share. Following this transaction, he directly holds 922 shares of common stoc", "url": "https://www.stocktitan.net/sec-filings/PSTV/form-4-plus-therapeutics-inc-insider-trading-activity-b2f1bef9b1b3.html", "source_name": "Stock Titan", "published_at": "2026-07-01T20:09:43", "published_display": "01 Jul 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PLUS Therapeutics (PSTV) director converts RSUs into 922 common shares", "summary": "PLUS Therapeutics director Kyle Guse exercised restricted stock units (RSUs) to acquire 922 shares of common stock at no cost. Following this transaction, Guse directly holds 922 common shares, with an additional 2,764 RSUs remaining outstanding, which will vest in quarterly inst", "url": "https://www.stocktitan.net/sec-filings/PSTV/form-4-plus-therapeutics-inc-insider-trading-activity-6c07411052d3.html", "source_name": "Stock Titan", "published_at": "2026-07-01T20:09:43", "published_display": "01 Jul 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] PLUS THERAPEUTICS, INC. Insider Trading Activity", "summary": "PLUS THERAPEUTICS director Richard J. Hawkins reported an insider trading activity involving the vesting of 922 Restricted Stock Units (RSUs) on July 1, 2026. This transaction was compensation-related, with each RSU converting into one share of common stock at $0.00 per share. Af", "url": "https://www.stocktitan.net/sec-filings/PSTV/form-4-plus-therapeutics-inc-insider-trading-activity-5919bab49dc7.html", "source_name": "Stock Titan", "published_at": "2026-07-01T20:09:43", "published_display": "01 Jul 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Plus Therapeutics (PSTV) CEO gains 16,439 shares from RSU vesting", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxOT0VQN3RXSy1DYm5TYjd3cDg3WUdjcXRkWGFWUDJGXzRZYlZvbU5MckZMOTJTMDM2SEF4dUItdF9xVG5NRG43bkNjRWE5Zi0xREtCZThLTGtsWWFfUEg4SnJnc3kzc1FRNVFUU0dHV1VvX3JMaUN2SDBPckU0aEpDNEtKWVE0R0FhWEtLZnRUTU9tREU4cWFLVE9lTFg2dEVsSEsxT0ljV0NMRVZ3X3IwdXRYZ19EZw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Plus Therapeutics (PSTV) director begins 4-part restricted stock unit vesting", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxPRTl2M255YWhPa1VLVjNFM2llVTRPaDc0bGdvSzJ5bVJRekNZaUx0RXRsdjdZQlRTOThQbzNkTnY5TDl4ZGNHQlRqQ0duVWpuVWlPcWFodGhxT3lqcGtMZmJQaGM0WjRzMzdBdmVFVzJ2bFNGUnpFTDZ3REZBcHNZeDZ0R2JfQThNUkw0ZDJFYUxSOFU0UXFzWDdiUU9USDM0NzltbjJOZXg0azN4WXQ4SmtXZEp5Zw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Plus Therapeutics to rebrand as Cerenome and adopt CNSY ticker on August 3 (PSTV)", "summary": "Plus Therapeutics, a healthcare company focusing on CNS cancers, announced it will rebrand as Cerenome and trade under the new Nasdaq ticker CNSY starting August 3, 2026. The company also reaffirmed its 2026 guidance, highlighting increased insurance coverage for its CNSide diagn", "url": "https://finance.yahoo.com/healthcare/articles/plus-therapeutics-rebrand-cerenome-adopt-124948664.html", "source_name": "Market source", "published_at": "2026-06-30T12:39:16", "published_display": "30 Jun 2026 12:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Plus Therapeutics to rebrand as Cerenome, change ticker to CNSY", "summary": "Plus Therapeutics (NASDAQ:PSTV) will rebrand as Cerenome and change its ticker symbol to CNSY, starting August 3, 2026. The company, which specializes in central nervous system cancers, currently trades at $4.29 with a market capitalization of $29.7 million, despite a 66.5% year-", "url": "https://www.investing.com/news/company-news/plus-therapeutics-to-rebrand-as-cerenome-change-ticker-to-cnsy-93CH-4767582", "source_name": "Investing.com", "published_at": "2026-06-30T11:39:16", "published_display": "30 Jun 2026 11:39", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Plus Therapeutics rebrands as Cerenome, ticker CNSY starts Aug. 3", "summary": "Plus Therapeutics (Nasdaq: PSTV) announced a rebranding to Cerenome with its ticker changing to CNSY, effective August 3, 2026. The company affirmed its 2026 milestone guidance, providing updates on REYOBIQ clinical trials, commercial expansion of its CNSide diagnostic platform, ", "url": "https://www.stocktitan.net/news/PSTV/plus-therapeutics-provides-mid-year-business-update-including-2cqma2y520bz.html", "source_name": "Stock Titan", "published_at": "2026-06-30T11:39:15", "published_display": "30 Jun 2026 11:39", "sentiment": "positive", "sentiment_pct": 78, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Plus Therapeutics Provides Mid-Year Business Update Including Corporate Rebranding", "summary": "Plus Therapeutics is rebranding to Cerenome and will trade under the new Nasdaq ticker CNSY starting August 3, 2026. This change reflects the company's integrated CNS oncology platform, combining therapeutics, diagnostics, and data analytics. The company also affirmed its 2026 gu", "url": "https://www.globenewswire.com/news-release/2026/06/30/3319554/0/en/plus-therapeutics-provides-mid-year-business-update-including-corporate-rebranding.html", "source_name": "GlobeNewswire", "published_at": "2026-06-30T11:39:15", "published_display": "30 Jun 2026 11:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of PLUS THERAPEUTICS, Inc. \u2013 NASDAQ:PSTV", "summary": "This article displays the title \"Price to earnings forward of PLUS THERAPEUTICS, Inc. \u2013 NASDAQ:PSTV\" and provides an overview of the company on TradingView. It indicates that the market is closed and no trades have occurred for PSTV. The content primarily focuses on navigation, m", "url": "https://www.tradingview.com/symbols/NASDAQ-PSTV/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T04:39:16", "published_display": "30 Jun 2026 04:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of PLUS THERAPEUTICS, Inc. \u2013 NASDAQ:PSTV", "summary": "This article provides financial data, specifically the \"Price to sales forward,\" for PLUS THERAPEUTICS, Inc. (NASDAQ: PSTV). It appears to be a financial snapshot from TradingView, offering details within a larger platform context. The content presents the \"Period,\" \"Value,\" \"Cha", "url": "https://www.tradingview.com/symbols/NASDAQ-PSTV/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T19:10:47", "published_display": "29 Jun 2026 19:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Plus Therapeutics to Provide Business Update Call on June 30, 2026", "summary": "Plus Therapeutics (Nasdaq: PSTV) announced it will host a business update call and webcast on Tuesday, June 30, 2026, at 8:30 a.m. Eastern Time. Management will discuss the CNSide\u00ae diagnostic launch, its integrated development plan for Reyobiq, and provide details on its CNS onco", "url": "https://www.globenewswire.com/news-release/2026/06/23/3315850/0/en/plus-therapeutics-to-provide-business-update-call-on-june-30-2026.html", "source_name": "GlobeNewswire", "published_at": "2026-06-27T06:09:04", "published_display": "27 Jun 2026 06:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Plus Therapeutics, Inc. Actuals & Estimates (DUS:XMP1)", "summary": "This article provides an overview of Plus Therapeutics, Inc. (DUS:XMP1) financials, analyst estimates, and key stock performance metrics. It includes details on past earnings, revenue, net income, and future earnings estimates. The article also covers the stock's highest and lowe", "url": "https://www.tradingview.com/symbols/DUS-XMP1/forecast-actuals-and-estimates/?category=cash_flow", "source_name": "TradingView", "published_at": "2026-06-27T02:40:11", "published_display": "27 Jun 2026 02:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Plus Therapeutics, Inc. Actuals & Estimates (GETTEX:XMP1)", "summary": "This article provides an overview of Plus Therapeutics, Inc. (XMP1) stock on GETTEX, including its current price, historical performance, analyst forecasts, and key financial metrics. It details income statement, balance sheet, and cash flow data, as well as upcoming earnings rep", "url": "https://www.tradingview.com/symbols/GETTEX-XMP1/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T15:39:44", "published_display": "26 Jun 2026 15:39", "sentiment": "negative", "sentiment_pct": 39, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Plus Therapeutics Secures National Coverage Agreement with Elevance Health for CNSide\u00ae Cerebrospinal Fluid Assay for Metastatic CNS Cancer", "summary": "Plus Therapeutics Inc., through its subsidiary CNSide Diagnostics, LLC, has announced a national agreement with Elevance Health, Inc. This agreement, effective May 1, 2026, extends coverage for the CNSide\u00ae Cerebrospinal Fluid (CSF) Tumor Cell Enumeration (TCE) assay to approximat", "url": "https://finance.yahoo.com/healthcare/articles/plus-therapeutics-secures-national-coverage-113000305.html", "source_name": "Market source", "published_at": "2026-06-25T23:11:14", "published_display": "25 Jun 2026 23:11", "sentiment": "positive", "sentiment_pct": 80, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Plus Therapeutics Unit Signs Coverage Agreement With Elevance Health for CNSide Assay", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/plus-therapeutics-unit-signs-coverage-121726944.html", "source_name": "MT Newswires", "published_at": "2026-06-25T12:17:26+00:00", "published_display": "25 Jun 2026 12:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Plus Therapeutics gets national health coverage for CNS cancer test", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPQ1p1TTZyc1lEcFd1eHRRZW1fUnlpX1B5U1gxeFltenVDc294MEtIczB0cWdXbGt5UWR6am5Rd2xSTi1mMHVSYkVLM1RHaGF3cXYwemR0czZyVkM5TC1TR0d2RzZpbUstZTdiT3RHQ3BuRV9GQ2JMYkVUN0NxZXRZQ3ZwT3BQbjhjNGdseVNmNGJQQmJZMG9kdTgwTDVYdk9PRG5BUjc4OWtCal9FWDh1VXFpcHQ0NjZTdmQ1eWFKdw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Plus Therapeutics to detail CNSide launch, Reyobiq plan June 30", "summary": "Plus Therapeutics (Nasdaq: PSTV) announced it will host a business update conference call and webcast on June 30, 2026, at 8:30 a.m. ET. Management plans to discuss the launch of its CNSide diagnostic, the integrated development plan for its lead drug Reyobiq, its CNS oncology st", "url": "https://www.stocktitan.net/news/PSTV/plus-therapeutics-to-provide-business-update-call-on-june-30-36v2qygbjoll.html", "source_name": "Stock Titan", "published_at": "2026-06-23T11:11:11", "published_display": "23 Jun 2026 11:11", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Plus Therapeutics Inc (PSTV) Risk Assessment: Volatility, Financial Risk & Investment Risk", "summary": "This article provides a risk assessment for Plus Therapeutics Inc (PSTV), detailing its volatility, financial risk, and investment risk. The company has a risk assessment score of 2.81, ranking 186 out of 388 in the Biotechnology & Medical Research industry, and its beta value of", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-pstv/risk-assesment", "source_name": "TradingKey", "published_at": "2026-06-17T09:40:35", "published_display": "17 Jun 2026 09:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Plus Therapeutics Inc (PSTV) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a detailed revenue breakdown for Plus Therapeutics Inc (PSTV) for fiscal year 2018, updated as of March 4, 2025. It categorizes revenue by business segments, including Consumable, Other products, and Device, and by geographic regions, specifically Japan, Ame", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-pstv/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T06:40:35", "published_display": "17 Jun 2026 06:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PLUS THERAPEUTICS, INC. SEC Filing (Jun 8, 2026)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxQOWN2bTFpaWhrTWVuVEctZW45ZlJHZWd0amZxNkpnRGVzYTVzdV8yMjBiMy1IaWJlTmRVdHVNcVpyUlpSZTBoTl9ia3c2blh0M2h2Wlk1UzhkdXpESy1aLVhtTFZndGUyTnNNWF84ajlwakRvQzE4bW4xSzFGWVN6eUwyWG14U2JfZEJFbzhjdUNZNnlHOHFjaFdLWnRLOUd3a3Ew?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Plus Therapeutics (NASDAQ: PSTV) sets $17,350,000 at-the-market stock program", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxPak1vVEQ4TnhFYlYxcVZBRFNfbjRObFUtNmg3dWxZMjNTSXF6OTlQUDA3and6OHRZa204WFIxUVVwd3JQcnpZUVBWamZPSl9aVGtveGZLUEd5YkpPc3hKVXJUR0JCcnY5U0lESFkyLW4xeERDek5FTldjajU3dE1vU0k5TmdZZnVZSzRjRUtIOXdsM3FDbVpCdHhCYVQ0OFNCczM4M0tYelRCOVRiZ2Uw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Plus Therapeutics gains CAP accreditation for CNSide CSF assay platform", "summary": "", "url": "https://finance.yahoo.com/m/d1b21ffe-1150-36de-8440-f3c64ad347ef/plus-therapeutics-gains-cap.html", "source_name": "Proactive", "published_at": "2026-06-04T16:17:00+00:00", "published_display": "04 Jun 2026 16:17", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What Do Plus Therapeutics' Latest Financials Tell Us", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxPekpCUVdsWFhIeS0xVGwtWWd2MVR5OHJQVkFXTlBoZ01aaFNoTWJiNmwzVjNMMVVpc1lOblVIdC1KV3pOYVhwMk9oRUNJQUxhX19uc1hkRF9jNzFWaWhKT0p3SUp4bDhJNld3MEp2S2lzdXpCRW05d2xBUE9zcEVHRUhXaVBVeEQ1cml3TUNUYw?oc=5", "source_name": "Kavout | AI", "published_at": "2026-05-16T00:05:51+00:00", "published_display": "16 May 2026 00:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Plus Therapeutics (PSTV) Reports Q1 Loss, Tops Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxOOUxjSVRTWlVTcDRBbVRGdmxCZUlBNEdOb2FXUnQ3TWFBTGNaampsOUtZODZPR3NfNHVYdE9BOVRNQUd5RF81bjlIODlGdkpGWEpwVkpYVExxYzNzY0lIdmFKZXpSYi1EWS1rTzRYTjh6WWhLeHY4Q1g2aGxTUVpWUnV3T1p1TXFvS1FDbUY5ZjJpMzVMVkdLcEtYem4waWhmU0dvNA?oc=5", "source_name": "Market source", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Plus Therapeutics stock gains after FDA orphan drug nod", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxQQXR3SE1YM2JBTHgtMHk3allveWJkckhOd0tuU2pQZXFPV3ZZM2pIdXNOYVFkRzdWMjhxejRkTEsxN3loUTYxNk9zQkNBY2J0YV90cm5lRk03WTZUb1VES2dVdGd1RjdoYmNzb0ZPc2IweG9taFAtczhReVd0bWphOXY1RWw0ZHdEZmVheEpLOU5HOUlYS0Q3b0Q0cEtHbmpLekhucDBuQ3ZFTDh2MGQ1Qy1WakpERDF6?oc=5", "source_name": "Investing.com", "published_at": "2026-04-08T07:00:00+00:00", "published_display": "08 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA grants orphan drug status to Plus Therapeutics\u2019 REYOBIQ", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxQTWdycXJpZmFIZm0yVUlPekh5T3pWTkE0eWpyaVdmS1BaSlBKckZZcGpyY0VuNEtlck8zNjBpVXJnenJSS2FqS3JzdG9Oek9GODVRQ1hzOFU3UDNKR0tlMVRNSGY1SFpxcTVrR2pGMll6b1pWMXVETl9fOUR5cWxIeUlBMnBuRmpUdHBQNEJldC1tR3FPU1BPQXU4M1M3SFpFMXBIQUxfcWFSalpobDBtekkycTAwUQ?oc=5", "source_name": "Investing.com", "published_at": "2026-04-08T07:00:00+00:00", "published_display": "08 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "D. Boral Capital Downgrades Plus Therapeutics (PSTV) to Hold", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxNa0JfWlJBYkpQZnpfNmdIMjVjTE1GZWp4Y0NLRjJHUkhibFQ4d0hiZ0Q1UWxjdzNLZG93OEt2TzJITUMxSTBUaEgxNU90Unk0N1ZuUWdaQjMxMC1hZnJvd1VTMTFmZjdHVkFObU5vTWpEeVZjUUNiOU9hem4yTUNiN3VtM3VETVdqb1pOUDR3RzIzQjBrcW5kZGk4czU?oc=5", "source_name": "Market source", "published_at": "2026-04-07T07:00:00+00:00", "published_display": "07 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Plus Therapeutics Announces Reverse Stock Split", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQYnhEZzFkTnR4aGVoRUttV1VraFZQc2JVMElONl9maENfMk8xS0VERjA1TF9MWDJycGRVbzZBN2pURDZPYXFHM1UwSUI2LXUzV0U0XzF3ZExUYTBQbm5MdTRLc1BtcHUwZjA2ZXl4cGZheklmSkNmMjJxM29CV2xWMS1LOGNjRWU2X19HNUJNQk44UXFObGNxdmt4bncwTGFZSDl3dC1Ga2gtdw?oc=5", "source_name": "Market source", "published_at": "2026-03-31T07:00:00+00:00", "published_display": "31 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Plus Therapeutics (PSTV) Reports Break-Even Earnings for Q4", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxPcV9yZ2d6NE9pWHVHTzVHMmEweE9UOEFvOURPa2Fsa3JCQ3JONk42bXVKUkR5bkY0al9qbGJzc05ZYzVGX2k0LXZySjVtU3F5YTRIN2VUNW5UTUktRF9heFZjYUhFbHp3LXJPTWwxWFB0VE5KNXFKenNVbXRYd1ROOGJkMC1RV2ZtMXc?oc=5", "source_name": "Market source", "published_at": "2026-03-12T07:00:00+00:00", "published_display": "12 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Analyst Revisions Are Rewriting The Story For Plus Therapeutics (PSTV)", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxOSTVvaEtiOUZSOWVPVnhBOHlnLURsUEN2ZjJEWFdsaURXNW5tTUE5em1VeGJFdWtXMUw4U0VxRjhBQzNlWmRVWU01Vnd1dVVnc09nZTJVdTBxWjJ5cjZwM3ZaVTEybEFOX3JZQzI2QTFoOHdCLXd2X1NhUk5HMGR0b1ZtR1dMYWRTN2syTQ?oc=5", "source_name": "Market source", "published_at": "2026-02-06T08:00:00+00:00", "published_display": "06 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Plus Therapeutics Provides Business Update on REYOBIQ\u2122 Clinical Program and U.S. CNSide\u00ae Commercialization", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxPUXZOLWNyNGZ6blY1dUVQZUF4NEEybEhBRGZwbEtrSlBWV1AzQVVzRXZ3dlA5aWRad3V0bmxaVU9tUnh6WkluUHIycm5qRlN1dHpaUXZtYWluLVdtSUFaRnlKdXE2ekJMMzhMNDVSZXRTX0xSOFpjcWdjS0JLSWVxcF9ONm1MbXlwc2lacWM1Nnh0cTA?oc=5", "source_name": "Market source", "published_at": "2026-01-22T08:00:00+00:00", "published_display": "22 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Plus Therapeutics plans CNS cancer test coverage for 150M US lives", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxQS211ak15NHFfSUhldWpQalR2U3VzbWZ5MzVhM3VQOUN5ME52Z2l2LUU4OHZSaE9IVXJqaGlZaVFmMHIxa3VUbDd5N3A0d2cxb1B5dDdKOXdSRFhhNG50Sk5QVnJ1WG9jWnN1OXc0Qm9DMWJ1eXRoY2ZDXzZzaThxUGwzZGJnTnl3a010Z3loMGhXMDkxczFTRkYtdFdYZ0IwU01sNmw4Zlhza1BNU3JsN3NxenktY0d4OUdn?oc=5", "source_name": "Stock Titan", "published_at": "2026-01-22T08:00:00+00:00", "published_display": "22 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Plus Therapeutics completes FDA meeting on REYOBIQ trial strategy", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPRHFPdUJ3YkxtVnlxblQ2YXViUER5YlJ2d0VYcGpQbS1lV21GODlzaVl5TkJkNlZvRDNNNTZkakVqYVZEa09DZFllMDdCa0E1NXlVeUVsdExvN1FrVURVOHB5bklzTHl2U01LN1FMQWxNc1dJOHlvZ1FIZHZWMnFueHVKSzRlMExOMk92eVNHa3hqYWJTUV9udkQ0VDRzWmVtUFFSa1JfR2w0SjJHV0RfOTk3OUtvcHBZX3RsdVZMQQ?oc=5", "source_name": "Investing.com", "published_at": "2026-01-08T08:00:00+00:00", "published_display": "08 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Plus Therapeutics stock falls after FDA meeting on REYOBIQ trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxQQkNzSkdmNE1hMWs2a3gyVGg3WVR5NHdqelZLbzhJenRnU24yTk9HTXo5cjVNWUdGb1U4ZVdsSGZNeXlOaFVyaEdwWEVkUDBZMGtEbTR4VHlTZm5kTk1EZ2hNSzNUdF9namNrd2xZNlZoOWp0cTJycmNyQmlGcExUMUFBSUdjNjIxc05MVkFYRnpZRVVHVzNXVGh3ZnFlancwLU1mdkJ3cnZzMVVWd281V0hPTlVKT2RHTXZKZFRRVC13d193?oc=5", "source_name": "Investing.com", "published_at": "2026-01-08T08:00:00+00:00", "published_display": "08 Jan 2026 08:00", "sentiment": "negative", "sentiment_pct": 22, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Plus Therapeutics Announces National Coverage Agreement with UnitedHealthcare Insurance Company for CNSide\u00ae Cerebrospinal Fluid Assay for Metastatic CNS Cancer", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgJBVV95cUxOZGh5eWxDV0QzU2NTMHlXVXcxYVRMbEM5Ql9lanpyel9FZVpQdWJLY2lZTGp3dGp2SzhOcVZ1WXJ2WjFjWERLbXRBTTR3el9fTFVNOEE3NWZtUFlqQTByTUJzOHRUTHFRdUJPSFdWZkRYbkgtOTYtajB6dHBFRXdLWmhfWXNESGZmYmtsZHJLZkxwT1BCd1MweHFUeVRKTXBMUWV2VGF0Q3BBX0pnclVwQ1ItNm5fcU9MTWEwblJIMmhkdzZEa1JVX2ViVlg3RXF6bTZocF84TlMydGtUbF9QMnA4cDcyUXc5b1BTRVUyOUlBeG5EbUhta0FnMVk1azRMVXZVVlJXZWs0b2tlTURCWXBadHBpdw?oc=5", "source_name": "Investing News Network", "published_at": "2025-09-25T07:00:00+00:00", "published_display": "25 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Plus Therapeutics Announces National Coverage Agreement with UnitedHealthcare For CNS Cancer Diagnostic Kit", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxQUnFtSmM1QzNRajhFenhkTEdqRFNmWENZam1jSURHRHdZZl8zbDV1Rk9xM3NGeG13M01OUk1maktabkkta253YXdkMU9nazItbVVmSnBvZlRVUGFHNTlrdTVQeHUyclFIYmdIQVJoSEJaeW5hcHVFSHJIalNhYmVjcVhLOVZvbjBYYXdheVpQaHhNOGg0cEE?oc=5", "source_name": "Market source", "published_at": "2025-09-25T07:00:00+00:00", "published_display": "25 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We Think Plus Therapeutics (NASDAQ:PSTV) Needs To Drive Business Growth Carefully", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-08-15T07:00:00+00:00", "published_display": "15 Aug 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 98, "total_relevant": 62, "sentiment_summary": {"positive": 18, "negative": 4, "neutral": 40, "score": 57, "total": 62, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 85, "events": [{"event": "general", "label": "Market update", "weight": 23.1, "count": 42}, {"event": "earnings", "label": "Earnings", "weight": 7.01, "count": 15}, {"event": "deals", "label": "Deals and strategy", "weight": 1.1, "count": 2}, {"event": "guidance", "label": "Guidance", "weight": 1.1, "count": 2}, {"event": "analyst", "label": "Analyst action", "weight": 0.55, "count": 1}], "positive_events": 18, "negative_events": 4}, "market_context": {"has_market_context": true, "latest_close": 3.74, "latest_week": "2026-07-17", "one_week_move": -6.5, "four_week_move": -11.0, "twelve_week_move": -43.3, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.087759, "market_dynamics_buy_signal": false, "relative_strength": -66.898307, "fair_value_gap": -86.5, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "undecided", "expectation_probability": 48.9088, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-6.5% over one week, -11.0% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 68, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 16}, {"label": "Stock Titan", "count": 15}, {"label": "Investing.com", "count": 5}, {"label": "TradingView", "count": 5}, {"label": "GlobeNewswire", "count": 3}, {"label": "simplywall.st", "count": 3}, {"label": "MT Newswires", "count": 2}, {"label": "TradingKey", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 53}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 42}, {"label": "Earnings", "count": 15}, {"label": "Deals and strategy", "count": 2}, {"label": "Guidance", "count": 2}, {"label": "Analyst action", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "57/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "85/100 classification confidence."}, {"label": "Company focus", "value": "53", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-6.5% over one week, -11.0% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Plus Therapeutics Secures Regional Coverage Agreement with Medical Mutual for CNSide\u00ae Cerebrospinal Fluid Assay for Metastatic CNS Cancer"}], "updated_at": "2026-07-23T10:28:26.093033+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}